Skip to main content

Advertisement

Table 2 Patient-reported change in EORTC QLQ-C30 scores from baseline to week 4 in the OXN-CR and OX-CR groups (FAS)

From: Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial

Variable Score at baseline Score at week 4 Score change from baseline to week 4
OXN-CR (n = 58) OX-CR (n = 59) OXN-CR (n = 36)a OX-CR (n = 31)a OXN-CR (n = 36)a P value OX-CR (n = 31)a P value
Global health status 3.74 ± 1.19 3.49 ± 1.34 3.88 ± 1.38 3.65 ± 1.21 −0.01 ± 1.34 0.951 −0.16 ± 1.50 0.554
Functional scales
 Physical functioning 1.89 ± 0.56 2.23 ± 0.67 2.14 ± 0.70 2.21 ± 0.67 0.29 ± 0.54 0.002 0.09 ± 0.54 0.360
 Role functioning 1.85 ± 0.77 2.40 ± 1.03 2.21 ± 0.86 2.42 ± 0.99 0.44 ± 0.87 0.002 0.24 ± 0.88 0.126
 Emotional functioning 1.72 ± 0.58 1.96 ± 0.65 1.86 ± 0.59 2.06 ± 0.84 0.15 ± 0.48 0.073 0.19 ± 0.69 0.241
 Cognitive functioning 1.53 ± 0.55 1.85 ± 0.63 1.92 ± 0.65 1.95 ± 0.85 0.35 ± 0.77 0.011 0.13 ± 0.59 0.280
 Social functioning 1.92 ± 0.70 2.12 ± 0.96 2.03 ± 0.70 2.15 ± 0.94 0.21 ± 0.85 0.200 0.11 ± 0.72 0.512
Symptoms scales/items
 Fatigue 2.13 ± 0.68 2.41 ± 0.76 2.44 ± 0.70 2.42 ± 0.80 0.35 ± 0.68 0.004 0.16 ± 0.74 0.234
 Nausea and vomiting 1.49 ± 0.73 1.63 ± 0.67 1.67 ± 0.85 1.68 ± 0.80 0.21 ± 0.65 0.055 0.03 ± 0.87 0.904
 Pain 2.35 ± 0.70 2.69 ± 0.71 2.44 ± 0.72 2.65 ± 0.95 0.14 ± 0.82 0.319 0.06 ± 0.85 0.831
 Dyspnea 1.48 ± 0.71 1.86 ± 0.86 1.89 ± 0.89 2.16 ± 0.90 0.42 ± 0.81 0.006 0.32 ± 0.87 0.058
 Insomnia 2.17 ± 0.92 2.20 ± 1.00 2.14 ± 0.87 2.19 ± 1.01 0.03 ± 1.08 0.944 0.10 ± 0.83 0.666
 Appetite loss 2.05 ± 0.87 2.34 ± 1.01 2.31 ± 1.06 2.35 ± 1.05 0.25 ± 1.02 0.188 0.13 ± 0.99 0.596
 Constipation 1.74 ± 0.85 1.81 ± 0.90 1.94 ± 0.83 2.26 ± 1.00 0.25 ± 0.81 0.081 0.48 ± 0.93 0.009
 Diarrhea 1.26 ± 0.58 1.49 ± 0.70 1.42 ± 0.73 1.23 ± 0.43 0.11 ± 0.92 0.505 −0.23 ± 0.50 0.039
 Financial difficulties 1.97 ± 0.86 2.15 ± 1.06 2.17 ± 0.97 2.16 ± 0.93 0.19 ± 1.04 0.231 −0.03 ± 0.60 1.000
  1. Results are presented as mean ± standard deviation
  2. EORTC QLQ-C30 European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-C30, OX-CR controlled-release oxycodone, OXN-CR controlled-release oxycodone/naloxone
  3. aPatients with available data at week 4. Scores for 22 patients in the OXN-CR group and 28 patients in the OX-CR group at week 4 were missing because these patients discontinued the study